Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Critical care (London, England)
- Publicado em
- 28 out 2024
- Citações
- 20
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
Patrick M Honoré, Massimo Girardis, Marin Kollef, Oliver A Cornely, George R Thompson, Matteo Bassetti, Alex Soriano, Haihui Huang, Jose Vazquez, Bart Jan Kullberg et al.
Descritores MeSH
- Candidemia
- Antifungal Agents
- Intensive Care Units
- Echinocandins
- Lipopeptides
- Candidiasis, Invasive
- Caspofungin
- Middle Aged
- Adult
- Aged
Veja também
Estudos relacionados
- Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses
- Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China)
- Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials
- Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials